Skip to main content
. Author manuscript; available in PMC: 2013 Nov 15.
Published in final edited form as: J Heart Lung Transplant. 2009 Mar 14;28(5):10.1016/j.healun.2009.01.015. doi: 10.1016/j.healun.2009.01.015

Figure 3.

Figure 3

The 5-year freedom from cardiac allograft vasculopathy was lower in the treated antibody-mediated rejection (TxAMR) and asymptomatic antibody-mediated rejection (AsAMR) groups compared with the control group. Cardiac allograft vasculopathy is defined as ≥ 30% stenosis in any vessel on an angiogram.